(Q54335658)

English

The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial.

scientific article published on 6 December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer: results from the Nordic ACT trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

single-nucleotide polymorphism

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

metastatic colon cancer

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

author name string

Torben Frøstrup Hansen

1

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

René dePont Christensen

2

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

Rikke Fredslund Andersen

3

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

Karen-Lise Garm Spindler

4

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

Anders Johnsson

5

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

Anders Jakobsen

6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

publication date

6 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

International Journal of Colorectal Disease

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

27

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

715-720

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

https://scigraph.springernature.com/pub.10.1007/s00384-011-1382-6

0 references

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

Angiogenesis in health and disease

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

The biology of VEGF and its receptors

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival.

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

The prognostic value of haplotypes in the vascular endothelial growth factor a gene in colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

A New Statistical Method for Haplotype Reconstruction from Population Data

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00384-011-1382-6

21 January 2018

The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22139032

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-angiogenic therapies for metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22139032

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The role of vascular endothelial growth factor genetic variability in cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/22139032

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00384-011-1382-6

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 May 2018

http://europepmc.org/abstract/MED/22139032

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54335658&oldid=1501723168"